Login to Your Account



ImmunoGen, Biogen Idec Sign TAP Deal Worth Up To $43M

By Randall Osborne


Thursday, October 7, 2004
Nailing down another deal with its Tumor-Activated Prodrug (TAP) technology, ImmunoGen Inc. is getting $1 million up front and as much as $42 million in milestone payments from Biogen Idec Inc., which is researching antibodies to an undisclosed tumor-cell target. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription